Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim N Chi

Showing results (81-90 of 234) with videos related to

Pageof 24
Sort By:
Cancer|April 23, 2008
C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trialTomasz M Beer, Alshad S Lalani, Stella Lee, et al.
European Journal of Cancer (Oxford, England : 1990)|June 15, 2021
Effectiveness of first-line abiraterone versus enzalutamide among patients ≥80 years of age with metastatic castration-resistant prostate cancer: A retrospective propensity score-weighted comparative cohort studyMaryam Soleimani, Kevin Zou, Katherine Sunderland, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|November 20, 2014
Treatment of muscle-invasive bladder cancer in Canada: A survey of genitourinary medical oncologists and urologistsTina Hsu, Peter C Black, Kim N Chi, et al.
Bioinformatics (Oxford, England)|August 18, 2016
SiNVICT: ultra-sensitive detection of single nucleotide variants and indels in circulating tumour DNACan Kockan, Faraz Hach, Iman Sarrafi, et al.
ACS Pharmacology & Translational Science|April 8, 2020
Revealing Metabolic Liabilities of Ralaniten To Enhance Novel Androgen Receptor Targeted TherapiesJon K Obst, Jun Wang, Kunzhong Jian, et al.
Future Oncology (London, England)|August 20, 2024
Prostate-specific antigen and health-related quality of life in individuals with advanced prostate cancer treated with apalutamide: a plain language summary of the SPARTAN and TITAN studiesLawrence I Karsh, Katherine B Bevans, Fred Saad, et al.
Cancer Chemotherapy and Pharmacology|July 6, 2010
A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancerSrikala S Sridhar, Christina M Canil, Kim N Chi, et al.
The New England Journal of Medicine|October 8, 2004
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancerIan F Tannock, Ronald de Wit, William R Berry, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|June 19, 2015
The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC)Fred Saad, Kim N Chi, Antonio Finelli, et al.
Current Oncology (Toronto, Ont.)|March 27, 2024
<sup>177</sup>Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: A Review of the Evidence and Implications for Canadian Clinical PracticeKim N Chi, Steven M Yip, Glenn Bauman, et al.
Pageof 24

Showing results (81-90 of 234) with videos related to

Sort By:
Pageof 24
Cancer|April 23, 2008
C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trialTomasz M Beer, Alshad S Lalani, Stella Lee, et al.
European Journal of Cancer (Oxford, England : 1990)|June 15, 2021
Effectiveness of first-line abiraterone versus enzalutamide among patients ≥80 years of age with metastatic castration-resistant prostate cancer: A retrospective propensity score-weighted comparative cohort studyMaryam Soleimani, Kevin Zou, Katherine Sunderland, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|November 20, 2014
Treatment of muscle-invasive bladder cancer in Canada: A survey of genitourinary medical oncologists and urologistsTina Hsu, Peter C Black, Kim N Chi, et al.
Bioinformatics (Oxford, England)|August 18, 2016
SiNVICT: ultra-sensitive detection of single nucleotide variants and indels in circulating tumour DNACan Kockan, Faraz Hach, Iman Sarrafi, et al.
ACS Pharmacology & Translational Science|April 8, 2020
Revealing Metabolic Liabilities of Ralaniten To Enhance Novel Androgen Receptor Targeted TherapiesJon K Obst, Jun Wang, Kunzhong Jian, et al.
Future Oncology (London, England)|August 20, 2024
Prostate-specific antigen and health-related quality of life in individuals with advanced prostate cancer treated with apalutamide: a plain language summary of the SPARTAN and TITAN studiesLawrence I Karsh, Katherine B Bevans, Fred Saad, et al.
Cancer Chemotherapy and Pharmacology|July 6, 2010
A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancerSrikala S Sridhar, Christina M Canil, Kim N Chi, et al.
The New England Journal of Medicine|October 8, 2004
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancerIan F Tannock, Ronald de Wit, William R Berry, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|June 19, 2015
The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC)Fred Saad, Kim N Chi, Antonio Finelli, et al.
Current Oncology (Toronto, Ont.)|March 27, 2024
<sup>177</sup>Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: A Review of the Evidence and Implications for Canadian Clinical PracticeKim N Chi, Steven M Yip, Glenn Bauman, et al.
Pageof 24